 |
 |
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Home | |
Products | |
Services | |
Technology | |
Investor Relations | |
Contact Us | |
|
|
Company Vision & StrategyWhite biotechnology has the capacity to change industrial biotechnology processes. For example, 75% of pharmaceutical active compounds are chiral compounds and the best way to make these efficiently is through biotech processes. A cheap source of compounds for the pharma industry is vital to its competitiveness.Bioprocesses already account for 15 million tons a year of chemical products including organic and amino acids, antibiotics, industrial and food enzymes, fine chemicals as well as active ingredients for crop protection, pharmaceutical products and fuel ethanol. White biotechnology can generate real revenue. White biotechnology also has an enormous potential because 99 percent of all microorganisms are still unknown. White biotechnology represents "a window of opportunity". Manufacturing financially viable and environmentally compatible products using MetGen's proprietary technology - is an opportunity not to be missed Pharmaceutical, Chemical and Forest industries are facing the similar challenges today
MetGen Oy is a Finnish company active in development and production of biopharmaceuticals and industrial enzymes for pharmaceutical industry. MetGen biocatalytical processes make the production of pharmaceuticals and industrial products faster, cleaner and less expensive. MetGen and its customers will benefit from turning low margin / high waste chemical production in to high margin/low waste biotransformation process. By using biotransformation methods provided by MetGen manufacturing can reduce the costs for about 70%. MetGen Strategy
MetGen addresses pyramid of market need by offering novel bioprocesses
|
|
|||||||||||||||||||||
